ProCE Banner Activity

Biomarker Testing in Prostate Cancer: An Essential Component in Transforming Care


Downloadable slideset from a medical oncologist and pathologist on testing for actionable mutations and using testing results to individualize PARP inhibitor–based therapy for patients with metastatic prostate cancer.

Released: March 27, 2024

Expiration: March 26, 2025



Himisha Beltran

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

Steven Christopher Smith

Steven Christopher Smith, MD, PhD

Associate Professor of Pathology and Surgery
Director, Genitourinary and Soft Tissue Pathology
VCU School of Medicine and Massey Comprehensive Cancer Center
Richmond, Virginia

Provided by

Provided by Clinical Care Options, LLC in partnership with the American Society for Clinical Pathology

ProCE Banner


Supported by an educational grant from Pfizer, Inc.

Pfizer, Inc.


American Society for Clinical Pathology

ProCE Banner